JP2002523426A - ｇｐ１２０に固有の形を有する抗シアノビリン抗体、その使用方法及びシアノビリンを用いてｇｐ１２０に対する免疫応答を誘導する方法 - Google Patents

ｇｐ１２０に固有の形を有する抗シアノビリン抗体、その使用方法及びシアノビリンを用いてｇｐ１２０に対する免疫応答を誘導する方法

Info

Publication number
JP2002523426A
JP2002523426A JP2000566308A JP2000566308A JP2002523426A JP 2002523426 A JP2002523426 A JP 2002523426A JP 2000566308 A JP2000566308 A JP 2000566308A JP 2000566308 A JP2000566308 A JP 2000566308A JP 2002523426 A JP2002523426 A JP 2002523426A
Authority
JP
Japan
Prior art keywords
cyanovirin
hiv
virus
cyanobilin
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2000566308A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002523426A5 (https=
Inventor
アール． ボイド、マイケル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Government of the United States of America
Original Assignee
Government of the United States of America
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Government of the United States of America filed Critical Government of the United States of America
Publication of JP2002523426A publication Critical patent/JP2002523426A/ja
Publication of JP2002523426A5 publication Critical patent/JP2002523426A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Disinfection or sterilisation of materials or objects, in general; Accessories therefor
    • A61L2/16—Disinfection or sterilisation of materials or objects, in general; Accessories therefor using chemical substances
    • A61L2/18—Liquid substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • AIDS & HIV (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2000566308A 1998-08-19 1999-08-19 ｇｐ１２０に固有の形を有する抗シアノビリン抗体、その使用方法及びシアノビリンを用いてｇｐ１２０に対する免疫応答を誘導する方法 Pending JP2002523426A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/136,594 US6193982B1 (en) 1995-04-27 1998-08-19 Anti-cyanovirin antibody with an internal image of gp120, a method of use thereof, and a method of using a cyanovirin to induce an immune response to gp120
US09/136,594 1998-08-19
PCT/US1999/018975 WO2000011036A1 (en) 1998-08-19 1999-08-19 AN ANTI-CYANOVIRIN ANTIBODY WITH AN INTERNAL IMAGE OF gp120, A METHOD OF USE THEREOF, AND A METHOD OF USING A CYANOVIRIN TO INDUCE AN IMMUNE RESPONSE TO gp120

Publications (2)

Publication Number Publication Date
JP2002523426A true JP2002523426A (ja) 2002-07-30
JP2002523426A5 JP2002523426A5 (https=) 2006-10-05

Family

ID=22473516

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000566308A Pending JP2002523426A (ja) 1998-08-19 1999-08-19 ｇｐ１２０に固有の形を有する抗シアノビリン抗体、その使用方法及びシアノビリンを用いてｇｐ１２０に対する免疫応答を誘導する方法

Country Status (6)

Country Link
US (1) US6193982B1 (https=)
EP (1) EP1107991A1 (https=)
JP (1) JP2002523426A (https=)
AU (1) AU746313B2 (https=)
CA (1) CA2340787A1 (https=)
WO (1) WO2000011036A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6428790B1 (en) * 1995-04-27 2002-08-06 The United States Of America As Represented By The Secretary Department Of Health And Human Services Cyanovirin conjugates and matrix-anchored cyanovirin and related compositions and methods of use
US7276227B2 (en) * 2002-02-25 2007-10-02 United States Of America, Repesented By The Secretary, Department Of Health And Human Services Obligate domain-swapped dimer of cyanovirin with enhanced anti-viral activity
AU2003276822A1 (en) * 2002-03-08 2004-02-02 Osel, Inc. Lactobacilli expressing biologically active polypeptides and uses thereof
US7491798B2 (en) * 2002-05-16 2009-02-17 The United States Of America As Represented By The Department Of Health And Human Services Scytovirins and related conjugates, fusion proteins, nucleic acids, vectors, host cells, compositions, antibodies and methods of using scytovirins
US7358334B1 (en) 2003-11-14 2008-04-15 Jay W Chaplin B cell-targeted toxins for humoral immune response reduction and methods of use thereof
US7456011B2 (en) * 2005-01-12 2008-11-25 Osel, Inc. Modified cyanovirin-n polypeptide
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
WO2019108656A1 (en) 2017-11-28 2019-06-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Microbicidal composition

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996034107A2 (en) * 1995-04-27 1996-10-31 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Antiviral proteins, dna coding sequences therefor, and uses thereof

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5266478A (en) 1987-05-29 1993-11-30 Tanox Biosystems, Inc. Antibodies which target a neutralization site within the second variable region of human immunodeficiency virus type 1 gp120
US5445960A (en) 1988-03-31 1995-08-29 The Arizona Board Of Regents On Behalf Of The University Of Arizona Monoclonal antibodies specific for HIV and hybridomas for their production
DE69029937T2 (de) 1989-04-25 1997-05-28 Tanox Biosystems Inc FÜr DIE CO4-BINDENDE DOMÄNE VON HIV SPEZIFISCHE ANTIKÖRPER
WO1991009625A1 (en) 1989-12-21 1991-07-11 Tanox Biosystems, Inc. Monoclonal antibodies which neutralize hiv-1 infection and their anti-idiotypes
SE9000333D0 (sv) 1990-01-31 1990-01-31 Britta Wahren Monoklonal antikropp
EP0651818B1 (en) 1990-05-16 1999-01-07 Dana Farber Cancer Institute Immunogenic peptides, antibodies and uses thereof relating to cd4 receptor binding
AP237A (en) 1990-05-29 1993-04-29 Cedars Sinai Medical Center Immunoreagents reactive with a conserved epitope of human immunodeficiency virus type 1 (HIV-1) gp120 and methods of use.
JP2989862B2 (ja) 1990-07-02 1999-12-13 財団法人化学及血清療法研究所 モノクローナル抗体
AU9072991A (en) 1990-10-26 1992-05-26 Public Health Research Institute Of The City Of New York, Inc., The Neutralizing human monoclonal antibodies specific for the v3 loop and cd-4 binding site of hiv-1 gp120
AU8900691A (en) 1990-11-19 1992-06-11 Queen's University At Kingston Hiv marker/aids vaccine
WO1992008491A1 (en) 1990-11-20 1992-05-29 Tanox Biosystems, Inc. Conjugates of anti-idiotype antibodies and carriers and their use in epitope-directed immunization
IE920785A1 (en) 1991-03-11 1992-09-23 Idec Pharma Corp Methods for selecting antibody reagents; anti-idiotype¹antibodies; and aids vaccine formulations
AU1538392A (en) 1991-03-11 1992-10-06 Idec Pharmaceuticals Corporation Methods for selecting antibody reagents; anti-idiotype antibodies; and aids vaccine formulations
JPH0570493A (ja) 1991-05-31 1993-03-23 Chemo Sero Therapeut Res Inst ヒト免疫不全ウイルス（ｈｉｖ）関連免疫調製物
AU659677B2 (en) 1991-08-22 1995-05-25 Nissin Shokuhin Kabushiki Kaisha HIV immunotherapeutics
US5558865A (en) 1991-08-22 1996-09-24 Nissin Shokuhin Kabushiki Kaisha HIV immunotherapeutics
AU2752892A (en) 1991-09-26 1993-04-27 Oklahoma Medical Research Foundation Fusion proteins targeted to lysosomes, for the treatment of aids
WO1993012232A1 (en) 1991-12-10 1993-06-24 Dana Farber Cancer Institute Reactive neutralizing human anti-gp120 recombinant antibody, dna coding the same and use thereof
EP0581353A1 (en) 1992-07-03 1994-02-02 De Staat Der Nederlanden Vertegenwoordigd Door De Minister Van Welzijn, Volksgezondheid En Cultuur Monoclonal antibodies to HiV-1 gp120, cell lines producing them and corresponding epitope structures
JPH08502260A (ja) 1992-09-30 1996-03-12 ザ スクリップス リサーチ インスティテュート ヒト免疫不全ウイルスに対するヒト中和モノクローナル抗体
US5652138A (en) 1992-09-30 1997-07-29 The Scripps Research Institute Human neutralizing monoclonal antibodies to human immunodeficiency virus
JPH06141885A (ja) 1992-11-05 1994-05-24 Chemo Sero Therapeut Res Inst モノクローナル抗体
US5817767A (en) 1993-02-24 1998-10-06 Progenics Pharmaceuticals, Inc. Synergistic composition of CD4-based protein and anti-HIV-1 antibody, and methods of using same
AU7203194A (en) 1993-06-04 1995-01-03 New York University Bispecific human monoclonal antibodies specific for human immunodeficiency virus
SE9302769D0 (sv) 1993-08-27 1993-08-27 Electrolux Ab Motorstyrning
US5618922A (en) 1994-07-25 1997-04-08 Nissin Shokuhin Kabushiki Kaisha NM03 antibody materials and methods

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996034107A2 (en) * 1995-04-27 1996-10-31 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Antiviral proteins, dna coding sequences therefor, and uses thereof

Also Published As

Publication number Publication date
US6193982B1 (en) 2001-02-27
WO2000011036A1 (en) 2000-03-02
EP1107991A1 (en) 2001-06-20
AU746313B2 (en) 2002-04-18
CA2340787A1 (en) 2000-03-02
AU5681499A (en) 2000-03-14
WO2000011036A9 (en) 2001-12-06

Similar Documents

Publication Publication Date Title
JP4081484B2 (ja) 抗ウイルス蛋白質、そのｄｎａコード配列およびその使用
CA2364500C (en) Cyanovirin conjugates, matrix-anchored cyanovirin and anti-cyanovirin antibody, and related compositions and methods of use
US6987096B1 (en) Antiviral proteins and peptides, DNA coding sequences therefor, and uses thereof
WO2002077189A2 (en) Glycosylation-resistant and nonglycosylated cyanovirins
JP2002523426A (ja) ｇｐ１２０に固有の形を有する抗シアノビリン抗体、その使用方法及びシアノビリンを用いてｇｐ１２０に対する免疫応答を誘導する方法
CA2441287C (en) Glycosylation-resistant cyanovirins and related conjugates, compositions, nucleic acids, vectors, host cells, methods of production and methods of using nonglycosylated cyanovirins
US5962668A (en) Nucleic acids encoding antiviral proteins and peptides fused to effector proteins
AU2002254382A1 (en) Glycosylation-resistant and nonglycosylated cyanovirins
US7048935B2 (en) Cyanovirin conjugates and matrix-anchored cyanovirin and related compositions and methods of use
AU2003252207C1 (en) Cyanovirin conjugates, matrix -anchored cyanovirin and anti-cyanovirin antibody, and related compositions and methods of use

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060817

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060817

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20091027

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100119

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100126

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100720